Immunogenicity of hepatitis B surface antigen derived from the baculovirus expression vector system: a mouse potency study

Roberta Attanasio; Robert E. Lanford; Dennis Dilley; Gregory W. Stunz; Lena Notvall; A. Burl Henderson; Ronald C. Kennedy

doi:10.1016/S1045-1056(05)80024-7

Immunogenicity of hepatitis B surface antigen derived from the baculovirus expression vector system: a mouse potency study

Roberta Attanasio, Robert E. Lanford, Dennis Dilley, Gregory W. Stunz, Lena Notvall, A. Burl Henderson, Ronald C. Kennedy

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

A standard mouse potency test was performed to evaluate the immunogenicity of recombinant hepatitis B surface antigen (HBsAg) produced in the baculovirus/insect cell expression system. Groups of NIH Swiss mice were immunized with serial four-fold amounts of either baculovirus-derived HBsAg adsorbed to aluminum sulfate or a commercially available yeast-derived recombinant HBsAg vaccine preparation. Results from these experiments showed that the effective dose of baculovirus-and yeast-derived HBsAg vaccine preparations necessary to seroconvert 50% of the animals were similar. The duration of the antibody response to HBsAg was studied in mice immunized with the highest doses of the two recombinant vaccine preparations 3 and 6 months after injection. No decrease in the anti-HBs response was observed 6 months after injection. No decrease in the anti-HBs response was observed 6 months after immunization with either of the two vaccine preparations. These results indicate that the baculovirus-derived recombinant HBsAg could serve as an alternative vaccine candidate for hepatitis B virus.

Original language	English (US)
Pages (from-to)	347-353
Number of pages	7
Journal	Biologicals
Volume	19
Issue number	4
DOIs	https://doi.org/10.1016/S1045-1056(05)80024-7
State	Published - Oct 1991

ASJC Scopus subject areas

Biotechnology
Bioengineering
Applied Microbiology and Biotechnology
Immunology and Microbiology(all)
Pharmacology

Access to Document

10.1016/S1045-1056(05)80024-7

Fingerprint Dive into the research topics of 'Immunogenicity of hepatitis B surface antigen derived from the baculovirus expression vector system: a mouse potency study'. Together they form a unique fingerprint.

Cite this

Immunogenicity of hepatitis B surface antigen derived from the baculovirus expression vector system : a mouse potency study. / Attanasio, Roberta; Lanford, Robert E.; Dilley, Dennis; Stunz, Gregory W.; Notvall, Lena; Henderson, A. Burl; Kennedy, Ronald C.

In: Biologicals, Vol. 19, No. 4, 10.1991, p. 347-353.

Research output: Contribution to journal › Article › peer-review

@article{e25bd8e39d424041812d96999d4cbb85,

title = "Immunogenicity of hepatitis B surface antigen derived from the baculovirus expression vector system: a mouse potency study",

abstract = "A standard mouse potency test was performed to evaluate the immunogenicity of recombinant hepatitis B surface antigen (HBsAg) produced in the baculovirus/insect cell expression system. Groups of NIH Swiss mice were immunized with serial four-fold amounts of either baculovirus-derived HBsAg adsorbed to aluminum sulfate or a commercially available yeast-derived recombinant HBsAg vaccine preparation. Results from these experiments showed that the effective dose of baculovirus-and yeast-derived HBsAg vaccine preparations necessary to seroconvert 50% of the animals were similar. The duration of the antibody response to HBsAg was studied in mice immunized with the highest doses of the two recombinant vaccine preparations 3 and 6 months after injection. No decrease in the anti-HBs response was observed 6 months after injection. No decrease in the anti-HBs response was observed 6 months after immunization with either of the two vaccine preparations. These results indicate that the baculovirus-derived recombinant HBsAg could serve as an alternative vaccine candidate for hepatitis B virus.",

author = "Roberta Attanasio and Lanford, {Robert E.} and Dennis Dilley and Stunz, {Gregory W.} and Lena Notvall and Henderson, {A. Burl} and Kennedy, {Ronald C.}",

note = "Funding Information: This work was supported in part by Grants AI-22307, AI-22380, and CA-53246. The authors wish to thank Ms Jo Fletcher for the excellent assistance in the preparatmn of this manuscript.",

year = "1991",

month = oct,

doi = "10.1016/S1045-1056(05)80024-7",

language = "English (US)",

volume = "19",

pages = "347--353",

journal = "Biologicals",

issn = "1045-1056",

publisher = "Academic Press Inc.",

number = "4",

}

TY - JOUR

T1 - Immunogenicity of hepatitis B surface antigen derived from the baculovirus expression vector system

T2 - a mouse potency study

AU - Attanasio, Roberta

AU - Lanford, Robert E.

AU - Dilley, Dennis

AU - Stunz, Gregory W.

AU - Notvall, Lena

AU - Henderson, A. Burl

AU - Kennedy, Ronald C.

N1 - Funding Information: This work was supported in part by Grants AI-22307, AI-22380, and CA-53246. The authors wish to thank Ms Jo Fletcher for the excellent assistance in the preparatmn of this manuscript.

PY - 1991/10

Y1 - 1991/10

N2 - A standard mouse potency test was performed to evaluate the immunogenicity of recombinant hepatitis B surface antigen (HBsAg) produced in the baculovirus/insect cell expression system. Groups of NIH Swiss mice were immunized with serial four-fold amounts of either baculovirus-derived HBsAg adsorbed to aluminum sulfate or a commercially available yeast-derived recombinant HBsAg vaccine preparation. Results from these experiments showed that the effective dose of baculovirus-and yeast-derived HBsAg vaccine preparations necessary to seroconvert 50% of the animals were similar. The duration of the antibody response to HBsAg was studied in mice immunized with the highest doses of the two recombinant vaccine preparations 3 and 6 months after injection. No decrease in the anti-HBs response was observed 6 months after injection. No decrease in the anti-HBs response was observed 6 months after immunization with either of the two vaccine preparations. These results indicate that the baculovirus-derived recombinant HBsAg could serve as an alternative vaccine candidate for hepatitis B virus.

AB - A standard mouse potency test was performed to evaluate the immunogenicity of recombinant hepatitis B surface antigen (HBsAg) produced in the baculovirus/insect cell expression system. Groups of NIH Swiss mice were immunized with serial four-fold amounts of either baculovirus-derived HBsAg adsorbed to aluminum sulfate or a commercially available yeast-derived recombinant HBsAg vaccine preparation. Results from these experiments showed that the effective dose of baculovirus-and yeast-derived HBsAg vaccine preparations necessary to seroconvert 50% of the animals were similar. The duration of the antibody response to HBsAg was studied in mice immunized with the highest doses of the two recombinant vaccine preparations 3 and 6 months after injection. No decrease in the anti-HBs response was observed 6 months after injection. No decrease in the anti-HBs response was observed 6 months after immunization with either of the two vaccine preparations. These results indicate that the baculovirus-derived recombinant HBsAg could serve as an alternative vaccine candidate for hepatitis B virus.

UR - http://www.scopus.com/inward/record.url?scp=0026333156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026333156&partnerID=8YFLogxK

U2 - 10.1016/S1045-1056(05)80024-7

DO - 10.1016/S1045-1056(05)80024-7

M3 - Article

C2 - 1797045

AN - SCOPUS:0026333156

VL - 19

SP - 347

EP - 353

JO - Biologicals

JF - Biologicals

SN - 1045-1056

IS - 4

ER -